Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.66 |
| ▸ | MAOB | P27338 | 4/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.66 |
| ▸ | SDHA | P31040 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | CALML3 | P27482 | 1/20 | 0.66 |
| ▸ | F10 | P00742 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6635018 | 0.88 | MAOA (0.74) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6635204 | 0.86 | CALML3 (0.56) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL27535197 | 0.84 | MAOA (0.71) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL14881432 | 0.83 | MAOA (0.78) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL14881430 | 0.83 | MAOA (0.78) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6615783 | 0.83 | MAOA (0.78) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6615781 | 0.83 | MAOA (0.78) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL7841797 | 0.82 | MAOA (0.74) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL7841802 | 0.82 | MAOA (0.74) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL5395906 | 0.82 | MAOA (0.70) | MAOAMAOBPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1330647-C | Heterobicyclic substituted phenyl * oxazolidinone antibacterial agents | ORTHO MCNELL PHARMACEUTICAL IN (US) | 2007-08-08 | — | — | CN | disclosed |
| US-6770664-B2 | PYRROLO(3,4-C)PYRAZOL-5(4H)-YL)-3-FLUOROPHENYL)-2-OXO-5 -OXAZOLIDINYL)METHYL)ACETAMIDE DERIVATIVES; BACTERICIDES AGAINST DRUG RESISTANT STAPHYLOCOCCUS, STREPTOCOCCUS, AND/OR ENTEROCOCCUS | PAGET STEVEN D (US) | 2004-08-03 | — | — | US | disclosed |
| US-20040067994-A1 | BICYCLIC HETEROCYCLIC SUBSTITUTED PHENYL OXAZOLIDINONE ANTIBACTERIALS, AND RELATED COMPOSITIONS AND METHODS | PAGET STEVEN D (US) | 2004-04-08 | — | — | US | disclosed |
| EP-1206469-B1 | ANTIBACTERIAL HETEROBICYCLIC SUBSTITUTED PHENYL OXAZOLIDINONES | ORTHO MCNEIL PHARM INC (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20030171366-A1 | Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods | PAGET STEVEN (US) | 2003-09-11 | — | — | US | disclosed |
| US-6608081-B2 | Treating pneumonia | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-08-19 | — | — | US | disclosed |
| CN-1414964-A | heterobicyclic substituted phenyl oxazolidinone antibacterial agents | ORTHO MCNELL PHARMACEUTICAL IN (US) | 2003-04-30 | — | — | CN | disclosed |
| US-20020161029-A1 | Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-10-31 | — | — | US | disclosed |
| US-6413981-B1 | DRUG-RESISTANT GRAM POSITIVE AND GRAM NEGATIVE BACTERIA; PNEUMONIA; INFECTIONS OF UPPER AND LOWER RESPIRATORY TRACT, SKIN, SOFT TISSUE, BONES AND JOINTS | ORTHO-MCNEIL PHARAMCEUTICAL, INC. | 2002-07-02 | — | — | US | disclosed |
| EP-1206469-A1 | ANTIBACTERIAL HETEROBICYCLIC SUBSTITUTED PHENYL OXAZOLIDINONES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001042242-A1 | ANTIBACTERIAL HETEROBICYCLIC SUBSTITUTED PHENYL OXAZOLIDINONES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161029-A1 | Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods | OXA1L, NDUFS3, CYCS | MAOA 456/4885MAOB 395/4885PTGS1 2228/4885 |
| US-20040067994-A1 | BICYCLIC HETEROCYCLIC SUBSTITUTED PHENYL OXAZOLIDINONE ANTIBACTERIALS, AND RELATED COMPOSITIONS AND METHODS | OXA1L, NDUFS3, CYCS | MAOA 456/4885MAOB 395/4885PTGS1 2228/4885 |
| US-20030171366-A1 | Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods | OXA1L, NDUFS3, CYCS | MAOA 443/4885MAOB 359/4885PTGS1 2171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.